377 related articles for article (PubMed ID: 25057921)
21. XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer.
Cheng Y; Holloway MP; Nguyen K; McCauley D; Landesman Y; Kauffman MG; Shacham S; Altura RA
Mol Cancer Ther; 2014 Mar; 13(3):675-86. PubMed ID: 24431073
[TBL] [Abstract][Full Text] [Related]
22. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
[TBL] [Abstract][Full Text] [Related]
23. Nuclear retention of Fbw7 by specific inhibitors of nuclear export leads to Notch1 degradation in pancreatic cancer.
Gao J; Azmi AS; Aboukameel A; Kauffman M; Shacham S; Abou-Samra AB; Mohammad RM
Oncotarget; 2014 Jun; 5(11):3444-54. PubMed ID: 24899509
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic Effects of XPO1 Inhibition in Thymic Epithelial Tumors.
Conforti F; Zhang X; Rao G; De Pas T; Yonemori Y; Rodriguez JA; McCutcheon JN; Rahhal R; Alberobello AT; Wang Y; Zhang YW; Guha U; Giaccone G
Cancer Res; 2017 Oct; 77(20):5614-5627. PubMed ID: 28819023
[TBL] [Abstract][Full Text] [Related]
25. Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
Liu Q; Mier JW; Panka DJ
Mol Cancer; 2011 Sep; 10():115. PubMed ID: 21929745
[TBL] [Abstract][Full Text] [Related]
26. Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related Lymphoma.
Boons E; Vanstreels E; Jacquemyn M; Nogueira TC; Neggers JE; Vercruysse T; van den Oord J; Tamir S; Shacham S; Landesman Y; Snoeck R; Pannecouque C; Andrei G; Daelemans D
EBioMedicine; 2015 Sep; 2(9):1102-13. PubMed ID: 26501108
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
[No Abstract] [Full Text] [Related]
28. XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.
Miyake T; Pradeep S; Wu SY; Rupaimoole R; Zand B; Wen Y; Gharpure KM; Nagaraja AS; Hu W; Cho MS; Dalton HJ; Previs RA; Taylor ML; Hisamatsu T; Kang Y; Liu T; Shacham S; McCauley D; Hawke DH; Wiktorowicz JE; Coleman RL; Sood AK
Clin Cancer Res; 2015 Jul; 21(14):3286-97. PubMed ID: 25878333
[TBL] [Abstract][Full Text] [Related]
29. Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.
Kashyap T; Argueta C; Aboukameel A; Unger TJ; Klebanov B; Mohammad RM; Muqbil I; Azmi AS; Drolen C; Senapedis W; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Nov; 7(48):78883-78895. PubMed ID: 27713151
[TBL] [Abstract][Full Text] [Related]
30. Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition.
Azmi AS; Muqbil I; Wu J; Aboukameel A; Senapedis W; Baloglu E; Bollig-Fischer A; Dyson G; Kauffman M; Landesman Y; Shacham S; Philip PA; Mohammad RM
Sci Rep; 2015 Nov; 5():16077. PubMed ID: 26536918
[TBL] [Abstract][Full Text] [Related]
31. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
[TBL] [Abstract][Full Text] [Related]
32. Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma.
Yoshimura M; Ishizawa J; Ruvolo V; Dilip A; Quintás-Cardama A; McDonnell TJ; Neelapu SS; Kwak LW; Shacham S; Kauffman M; Tabe Y; Yokoo M; Kimura S; Andreeff M; Kojima K
Cancer Sci; 2014 Jul; 105(7):795-801. PubMed ID: 24766216
[TBL] [Abstract][Full Text] [Related]
33. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa).
Gravina GL; Tortoreto M; Mancini A; Addis A; Di Cesare E; Lenzi A; Landesman Y; McCauley D; Kauffman M; Shacham S; Zaffaroni N; Festuccia C
J Hematol Oncol; 2014 Oct; 7():46. PubMed ID: 25284315
[TBL] [Abstract][Full Text] [Related]
34. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
[TBL] [Abstract][Full Text] [Related]
35. Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.
Sabbatino F; Wang Y; Scognamiglio G; Favoino E; Feldman SA; Villani V; Flaherty KT; Nota S; Giannarelli D; Simeone E; Anniciello AM; Palmieri G; Pepe S; Botti G; Ascierto PA; Ferrone CR; Ferrone S
J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26851802
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of XPO1 with KPT-330 induces autophagy-dependent apoptosis in gallbladder cancer by activating the p53/mTOR pathway.
Zhao C; Yang ZY; Zhang J; Li O; Liu SL; Cai C; Shu YJ; Pan LJ; Gong W; Dong P
J Transl Med; 2022 Sep; 20(1):434. PubMed ID: 36180918
[TBL] [Abstract][Full Text] [Related]
37. Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.
Khan HY; Ge J; Nagasaka M; Aboukameel A; Mpilla G; Muqbil I; Szlaczky M; Chaker M; Baloglu E; Landesman Y; Mohammad RM; Azmi AS; Sukari A
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905765
[TBL] [Abstract][Full Text] [Related]
38. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
39. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.
Lapalombella R; Sun Q; Williams K; Tangeman L; Jha S; Zhong Y; Goettl V; Mahoney E; Berglund C; Gupta S; Farmer A; Mani R; Johnson AJ; Lucas D; Mo X; Daelemans D; Sandanayaka V; Shechter S; McCauley D; Shacham S; Kauffman M; Chook YM; Byrd JC
Blood; 2012 Nov; 120(23):4621-34. PubMed ID: 23034282
[TBL] [Abstract][Full Text] [Related]
40. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
